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Introduction
In recent years, studies have shown unequivocally that the 
use of combination antiretroviral regimens, for either treat-
ment or prophylaxis, during the antenatal, intrapartum 
and breastfeeding periods in women with human immu-
nodeficiency virus (HIV) infections can reduce the rate of 
transmission to their infants to less than  5%.1–3 The World 
Health Organization (WHO) has endorsed this approach to 
the prevention of mother-to-child transmission (PMTCT) of 
the human immunodeficiency virus (HIV), which it terms the 
Option B strategy. It is relatively simple, is aligned with adult 
HIV treatment guidelines, is associated with a reduction in 
comorbid conditions related to acquired immunodeficiency 
syndrome (AIDS), and can limit HIV transmission to unin-
fected partners.4,5 In fact, this approach has been extended in 
many settings into what has been termed Option B+, where 
antiretroviral therapy (ART) is started during pregnancy for 
all HIV-infected pregnant women and continued for life.6
Although maternal antiretroviral regimens have been 
shown to be highly effective in clinical trials, the results are 
difficult to replicate fully in real world settings,7 largely because 
of inefficiencies in health systems.8 For example, incomplete 
uptake of health-care services in a community can result 
in poor coverage of proven biomedical interventions.9,10 In 
addition, delays in screening patients for their eligibility 
for antiretroviral prophylaxis or treatment can result in late 
drug administration.11 There is also growing evidence in the 
literature suggesting that, after therapies have been started, 
treatment adherence and programme retention may be poor 
among HIV-infected pregnant and breastfeeding women.12–14
Research on the implementation of antiretroviral pro-
grammes for PMTCT is needed to extend our understanding 
of the efficacy of these interventions in individuals to their 
effectiveness in the general population.15,16 This broader 
understanding is urgently needed by policy-makers and 
programme managers who are planning to adopt or optimize 
maternal combination antiretroviral regimens for PMTCT in 
various settings.6,17,18 The aim of this study was to evaluate, at 
the population level, a pilot PMTCT programme similar to 
Option B in rural Zambia (Table 1). Cross-sectional household 
surveys were performed before and after implementation of 
the programme to determine whether early childhood survival 
in the community changed during this time.
Methods
The pilot programme
In April 2009, we implemented a pilot PMTCT programme 
at four health-care facilities in the rural Kafue district of 
Zambia using a phased approach. With support from the 
Zambian Ministry of Health, we offered standard combination 
antiretroviral regimens to all HIV-infected pregnant women, 
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irrespective of immunological status. 
A detailed description of the clinical 
services provided has been presented 
elsewhere.19 Briefly, consistent with the 
standard of care in Zambia, all pregnant 
women who sought antenatal care were 
offered opt-out HIV counselling and 
testing; those who tested positive un-
derwent clinical and immunological (i.e. 
CD4+ T-cell count) screening. These 
evaluations were required by national 
treatment guidelines and were used to 
determine whether the maternal ART 
should be continued after breastfeeding. 
In addition, since virological monitor-
ing was not routinely available, these 
baseline data were also important for 
assessing treatment responses. Women 
who met Zambian national guideline 
criteria for HIV treatment (i.e. a CD4+ 
T-cell count less than 350 cells/µl or 
WHO clinical stage 3 or 4) immediately 
started lifelong antiretroviral therapy.20
In our programme, we also offered 
three-drug combination regimens 
to women who did not meet these 
eligibility criteria, starting at 28 weeks’ 
gestation and continuing until the ces-
sation of breastfeeding. The regimens 
were based on the nucleoside reverse 
transcriptase inhibitors zidovudine 
and lamivudine, which were combined 
with either nevirapine or efavirenz. (At 
the time, Zambian PMTCT guidelines 
recommended zidovudine monotherapy 
for HIV-infected pregnant women from 
28 weeks’ gestation until delivery and 
nevirapine peripartum for mother and 
neonate but no antiretrovirals during 
breastfeeding.)21 Although we imple-
mented this pilot programme before 
2010, when WHO first recommended 
antiretroviral prophylaxis during breast-
feeding, this regimen closely resembles 
Option B, as described in later WHO 
guidelines (Table 1).4
Household surveys
To measure changes associated with the 
PMTCT programme at the population 
level, we conducted two household 
surveys in the catchment areas of the 
four health-care facilities taking part. 
We used the methods first introduced in 
the four-country study to measure the 
24-month HIV-free survival in children 
born to HIV-infected mothers.22 We as-
sessed survival using methods similar to 
those used in Demographic and Health 
Surveys conducted in many African 
countries.23 The sampling method was 
established in the first survey, which 
was conducted between November 2008 
and May 2009, before implementation of 
the pilot PMTCT programme. Govern-
ment-demarcated catchment areas were 
mapped and we randomly selected zones 
within these communities. These zones 
were used by each health-care facility’s 
Neighbourhood Health Committee for 
community outreach. We identified a 
central point in each zone and used a 
spin-the-bottle approach to select the 
starting point for enumeration.24 In-
dividual residences were then selected 
at a predefined spacing interval, which 
was based on the estimated population 
of each catchment area. The residences 
were sampled in a clockwise direction 
until the whole zone had been can-
vassed. Team members then went to the 
next zone on the list and started the pro-
cess anew. In the first survey, sampling 
continued until 387 eligible households, 
as defined below, had been surveyed in 
each community. If the target number 
was reached midway through a zone, 
sampling was completed for that zone. 
The second survey was conducted in the 
same zones, used the same predefined 
residence spacing intervals and took 
place between March and December 
2011, at least two years after the PMTCT 
programme had been introduced at each 
health-care facility. However, since the 
starting point for canvassing households 
in each zone was randomly selected, the 
two surveys did not necessarily include 
the same households.
At each household, trained enumer-
ators identified the head of the household 
and administered a screening ques-
tionnaire. If a household member was 
reported to have given birth in the last 
two years, written consent was requested 
for the use of an additional questionnaire 
with 165-questions to collect more data 
on the demographic and socioeconomic 
characteristics of the household and 
on the medical history of the child’s 
mother. Separate written consent was 
also requested for the collection of blood 
specimens from eligible mothers and 
children. Maternal samples were tested 
for HIV antibodies and specimens from 
children who were exposed to HIV (i.e. 
because their mothers were seropositive) 
were tested for HIV deoxyribonucleic 
acid using polymerase chain reaction. 
In households in which a newborn child 
had died within the past two years, survey 
staff administered a comprehensive ver-
bal autopsy questionnaire.25 If members 
of a selected household were not available 
at the time of the initial visit, enumerators 
returned up to three times and sched-
uled appointments to meet with either 
the head of the household or the child’s 
mother or both.
The primary outcome measure was 
the proportion of HIV-exposed chil-
dren that were alive and HIV-uninfect-
ed at 24 months of age (i.e. 24-month 
HIV-free survival). We hypothesized 
Table 1. Characteristics of a pilot programme to prevent mother-to-child transmission 
(PMTCT) of the human immunodeficiency virus (HIV) in the Kafue district of 
Zambia, 2009–2011, and the World Health Organization’s strategies
Characteristic Zambian pilot 
programme
WHO strategy
Option B4 Option B+5




antiretroviral regimen during 
pregnancy and labour
Yes Yes Yes
Gestational age at regimen 
initiation
28 weeks or later 14 weeks or later 14 weeks or later
Timing of infant prophylaxis 
with zidovudine or 
nevirapine
First week of life First 6 weeks 
of life
First 6 weeks 
of life
Maternal combination 
antiretroviral regimen during 
breastfeeding
Yes Yes Yes
Continuation of combination 
antiretroviral regimens after 
cessation of breastfeeding
Only for those eligible 
for HIV treatment 
according to adult 
guidelines






treatment for all 
women
ART: antiretroviral therapy; WHO: World Health Organization.
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that the proportion would increase 
between the two surveys from 50% to 
75%.26 To achieve a power of 80% with 
an α of 0.05 using the χ2 test, we needed 
to enrol 58 HIV-exposed children born 
within the last two years from each of 
the four study sites. Assuming an esti-
mated prevalence of HIV infection of 
15%, we calculated that we needed to 
include a minimum of 387 households 
with a child under the age of two years 
in each community.
Statistical methods
We compared participants in the two 
surveys. Differences in categorical 
variables were assessed using Pearson’s 
χ2 test after we confirmed that the test’s 
assumptions were valid in each case. 
Differences in continuous variables 
were assessed using nonparametric 
Wilcoxon rank-sum tests. The overall 
HIV-free survival rate in HIV-exposed 
children was derived for each survey 
using a parametric survival model with 
a Weibull distribution. A Weibull mod-
el was considered appropriate following 
graphical exploration of the baseline 
hazard. We also examined differences 
in HIV-free survival between the two 
surveys in each individual community 
using the same approach. Further, we 
identified factors associated with HIV 
infection or death by calculating ad-
justed hazard ratio (aHR) using Weibull 
regression with interval censoring and 
adjustment for clustering. The vari-
ables selected a priori for inclusion 
in our multivariable models were the 
PMTCT therapy, maternal age, parity, 
educational level and marital status, in-
stitutional antenatal care, institutional 
delivery and infant breastfeeding. In 
addition, a binary variable for whether 
the data were collected in the first or 
second household survey (i.e. before or 
after programme implementation) was 
included to take into account unmea-
sured time trends between the surveys. 
Because extensive information was col-
lected in the household questionnaires, 
the multivariable models included 
socioeconomic and children’s health 
factors that were associated with HIV-
free survival at a statistical significance 
level of P < 0.10. A factor was excluded 
if it did not appear to be independent of 
other factors included in the proposed 
model. We controlled for the survey site 
using the strata option in Stata version 
12.1 (StataCorp. LP, College Station, 
United States of America). Further, 
to correct for possible correlations 
within sites, we employed a sandwich 
estimator to obtain robust standard 
errors using the vce(robust) option. In 
addition, because we were interested in 
the detailed effect of the pilot PMTCT 
programme on programme outcomes, 
we used Pearson’s χ2 test to compare the 
utilization of specific PMTCT services 
between respondents who took part 
in the first and second surveys. For all 
analyses, we considered P < 0.05 to be 
statistically significant.
The study was approved by the Bio-
medical Research Ethics Committee of 
the University of Zambia and the institu-
tional review boards of the University of 
North Carolina at Chapel Hill and of the 
University of Alabama at Birmingham in 
the United States.
Results
In total, 31 zones were visited in each 
of the two surveys: seven in Chipapa, 
six in Kafue Estates, nine in Kafue Mis-
sions and nine in Mount Makulu. In 
the first survey, 3636 households were 
approached, 1947 (53.5%) of which were 
found to be eligible (Fig. 1). Informa-
tion about maternal HIV status was 
available for 1778 (97.2%) of the 1830 
children aged under two years in these 
households; 335 (18.8%) were found to 
be HIV-exposed. In the second survey, 
5801 households were approached, 
2441 (42.1%) of which were found to 
be eligible. Information about maternal 
HIV status was available for 2386 of 
2444 (97.6%) children aged under two 
years and 390 (16.3%) were found to be 
HIV-exposed. The geographical distri-
bution of eligible households sampled 
in the second survey is shown in Fig. 2 
– comparable data were not collected in 
the first survey.
There were significant differences in 
household and maternal characteristics 
between the two surveys (Table 2). So-
cioeconomic conditions were better in 
the second survey than the first: house-
holds in the second survey were sig-
nificantly more likely to report having a 
water supply, a finished floor, electricity, 
a refrigerator, a television and a mobile 
phone (P < 0.0001 for all). The preva-
lence of HIV infection among mothers 
appeared to decline between the surveys, 
from 18.8% to 16.3% (P < 0.071), and the 
proportion of women who gave birth 
Fig. 1. Community surveys before and during the pilot programme to prevent mother-
to-child transmission (PMTCT) of the human immunodeficiency virus (HIV) in the 





1830 children aged 
<2 years participated
1947 households 
eligible (contains child 
born in last two years)









10 HIV status unknown
31 dead)
1996 not HIV-exposed
(1943 alive, 53 dead)
47 whose mother’s HIV 
status was unknown
(45 alive, 2 dead)
11 whose mother died
(11 alive)
1443 not HIV-exposed
(1354 alive, 89 dead)
38 whose mother’s HIV 
status was unknown
(32 alive, 6 dead)
14 whose mother died
(10 alive, 4 dead)
2441 households 
eligible (contains child 













2444 children aged 
<2 years participated
First surveya Second surveyb
a  The first survey was conducted between November 2008 and May 2009, before implementation of the 
PMTCT pilot programme.
b  The second survey was conducted between March and December 2011, at least two years after the 
PMTCT pilot programme had been introduced.
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at a health-care facility increased from 
58.0% to 67.8% (P < 0.0001). The chil-
dren’s’ characteristics appeared similar 
in the two surveys. In particular, there 
was no significant difference in their 
median age: 10.9 months in the first 
survey versus 10.8 months in the second 
(P = 0.081, Table 2).
The cumulative estimated 24-month 
survival in HIV-exposed children was 
significantly higher in the second sur-
vey than the first: 0.97 (95% confidence 
interval, CI: 0.95–0.99) versus 0.87 (95% 
CI: 0.84–0.95), respectively (Fig. 3). The 
difference in the estimated 24-month 
HIV-free survival was even more pro-
nounced: 0.89 (95% CI: 0.83–0.94) in 
the second survey versus 0.66 (95% CI: 
0.63–0.76) in the first (Fig. 4). These 
trends were consistent across all four 
communities. Multivariate analysis 
showed that the risk of HIV infection 
or death was significantly lower in the 
children of mothers who started a com-
bination antiretroviral regimen during 
pregnancy than in those whose mothers 
had no antiretroviral prophylaxis (aHR: 
0.33, 95% CI: 0.15–0.73). Moreover, 
even after adjustment for potential 
demographic and socioeconomic con-
founders, children in the second survey 
were less likely to acquire an HIV infec-
tion or die than those in the first (aHR: 
0.52, 95% CI: 0.34–0.80; Table 3).
To assess the contribution of the pi-
lot PMTCT programme to the observed 
improvement in the HIV-free survival 
rate in children, we examined differenc-
es in the utilization of specific PMTCT 
services between the surveys. Increases 
were observed between the first and 
second surveys in four key indicators 
in HIV-infected mothers (i.e. those who 
tested positive at the time of the survey): 
(i) the proportion who knew their HIV 
status (from 74.4% to 91.9%, P < 0.0001; 
Fig. 5, available at: http://www.who.
int/bulletin/volumes/92/8/13-129833); 
(ii) the proportion who were tested for 
HIV during their last pregnancy (from 
76.4% to 88.1%, P < 0.0001; Fig. 6, avail-
able at: http://www.who.int/bulletin/voll-
umes/92/8/13-129833); (iii) the propor)-
tion who reported using any antiretro-
viral prophylaxis during their last preg-
nancy (from 42.5% to 67.5%, P < 0.0001; 
Fig. 7, available at: http://www.who.int/
bulletin/volumes/92/8/13-129833); and 
(iv) the proportion who reported using 
combination antiretroviral regimens 
Fig. 2. Geographical distribution of eligible households in the second community surveya during the pilot programme to prevent 
mother-to-child transmission (PMTCT) of the human immunodeficiency virus (HIV) in the Kafue district of Zambia, 2009–2011




Chipapa rural health clinic
Kafue Estates clinic
Kafue Missions rural health clinic
0 2.5 5 10
kilometres
a  Comparable data were not collected in the first survey.
Source: map produced using ArcGIS® (Esri, Redlands, United States of America) and shapefile of roadmap.27
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Table 2. Characteristics of households, mothers and children in a pilot programme to prevent mother-to-child transmission (PMTCT) of 
the human immunodeficiency virus (HIV) the Kafue district of Zambia, 2009–2011
Characteristica No. (%) of households, mothers or childrena Pd





Water supply < 0.0001
  Piped water to house 256 (14.0) 401 (16.4)
  Piped water outside but available within grounds 437 (23.9) 516 (21.1)
  Public tap 379 (20.7) 704 (28.8)
  Other 758 (41.4) 823 (33.7)
Toilet facilities 0.026
  Flush toilet or pit latrine 1600 (87.4) 2161 (88.4)
  None 230 (12.6) 283 (11.6)
Main floor material < 0.0001
  Finished floor (i.e. cement, tiles, wood or planks) 1094 (59.8) 1672 (68.4)
  Natural floor (i.e. earth, mud, dung or sand) 735 (40.2) 758 (30.9)
  Data missing 1 (0.1) 17 (0.7)
Electricity 581 (31.7) 1032 (42.2) < 0.0001
Refrigerator 353 (19.3) 641 (26.2) < 0.0001
Television 705 (38.5) 1079 (44.1) < 0.0001
Mobile phone 1103 (60.3) 1990 (81.4) < 0.0001
Maternal characteristics
Age at survey in years, median (IQR) 26 (21–31) 25 (21–30) 0.003
Parity, median (IQR) 2 (1–4) 2 (1–3) 0.0002
Marital status 0.075
  Married or cohabitating 1531 (83.7) 2093 (85.6)
  Other 299 (16.3) 351 (14.4)
Educational level 0.034
  Primary schooling or none at all 924 (50.5) 1314 (53.8)
  Secondary or higher 906 (49.5) 1130 (46.2)
Currently employed 697 (38.1) 1068 (43.7) < 0.0001
HIV status (laboratory data; n = 1778 and n = 2386)e 0.071
  Positive 335 (18.8) 390 (16.3)
  Negative 1443 (81.2) 1996 (83.7)
Enrolled for antenatal care during last pregnancy 1729 (94.5) 2392 (97.9) < 0.0001
Gestational age when antenatal care started, in weeks (n = 1720 and 
n = 2393), median (IQR)
20 (16–24) 20 (16–24) 0.488
Delivery in a health-care facility 1061 (58.0) 1658 (67.8) < 0.0001
Child’s characteristics
Age at survey in months, median (IQR) 10.9 (4.6–16.9) 10.8 (5.2–17.3) 0.081
Birth weight in grams (n = 1179 and n = 1791),e median (IQR) 3000 (2800–3500) 3050 (2700–3400) 0.144
Birth weight ≤ 2500 g 193 (10.5) 300 (12.3) < 0.0001
Feeding method in first 6 months of life (children aged > 6 months only, 
n = 1256 and n = 1747)e
  Exclusively breastfed 1088 (86.6) 1660 (95.0) < 0.0001
  Mixed feeding 148 (11.8) 34 (1.9)
  Formula feeding only 14 (1.1) 21 (1.2)
  Data missing 6 (0.5) 32 (1.8)
IQR: interquartile range.
a  No. (%) unless otherwise stated in row headers.
b  The first survey was conducted between November 2008 and May 2009, before implementation of the PMTCT programme.
c  The second survey was conducted between March and December 2011, at least two years after the PMTCT programme had been introduced.
d  Categorical variables were compared using Pearson’s χ2 test and continuous variables were compared using the Wilcoxon rank-sum test.
e  The number of women or children for whom the information was available in the first and second surveys, respectively.
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during their last pregnancy (from 13.3% 
to 45.3%, P < 0.0001; Fig. 8).
Discussion
Our study used before and after house-
hold surveys to assess the changes, at 
the population level, associated with 
a pilot PMTCT programme similar 
to WHO’s Option B. We observed a 
dramatic increase in the 24-month 
HIV-free survival rate among children 
born to HIV-infected mothers in our 
four targeted communities. However, 
because our study was not random-
ized and did not include a control 
group, we were not able to attribute 
this improvement to the provision of 
combination antiretroviral regimens 
to HIV-infected pregnant women in 
our pilot programme. Nevertheless, 
our findings indicate that increased 
investment in PMTCT can have a posi-
tive effect on early childhood health 
outcomes at the population level even 
though it was difficult to quantify the 
influence of individual components of 
the programme.
Our study had several other limi-
tations in addition to the absence 
of randomization and the lack of a 
control group. First, the significant 
differences observed between our two 
survey populations, particularly in 
household indicators of socioeconomic 
status, were unexpected and could have 
contributed to a general improvement 
in health. Although we attempted to 
adjust for these factors in our multi-
variate analysis, there remained a risk of 
residual confounding. Moreover, other 
studies carried out in these communi-
ties between 2008 and 2011 may also 
have contributed to improved health 
outcomes.28–30 Second, the number of 
HIV infections and deaths among HIV-
exposed children was relatively small. 
However, the use of statistical models 
to estimate the 24-month HIV-free 
survival rate in children increased the 
precision of our estimates. Finally, in 
this analysis we did not explore reasons 
for the lower than expected uptake of 
maternal ART during pregnancy in the 
four communities. We plan to carry out 
a secondary analysis using the survey 
data to address this issue. However, 
given the likely heterogeneity of partici-
pants’ characteristics between the study 
communities, more extensive qualitative 
research may be needed.
Fig. 3. Estimated survival of children born to HIV-infected mothers before and after the 
pilot programme to prevent mother-to-child transmission (PMTCT) of the human 
immunodeficiency virus (HIV) in the Kafue district of Zambia, 2009–2011
Time from birth (months)
Estimated survival (95% CI) second survey, 2011
Estimated survival (95% CI) first survey, 2008–2009

























Fig. 4. Estimated HIV-free survival of children born to HIV-infected mothers before and 
after the pilot programme to prevent mother-to-child transmission (PMTCT) 
of the human immunodeficiency virus (HIV) in the Kafue district of Zambia, 
2009–2011
Time from birth (months)
Estimated HIV-free survival (95% CI) second survey, 2011
Estimated HIV-free survival (95% CI) first survey, 2008–2009
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Although we observed a more than 
threefold increase in the utilization of 
combination antiretroviral regimens 
between the first and second surveys, 
the rates were modest, at 13.3% and 
45.3%, respectively. Since fewer than 
half of HIV-infected pregnant women 
received this intervention, it is unlikely 
that the pilot PMTCT programme alone 
could have produced such a dramatic 
increase in HIV-free survival in chil-
dren. Better survival could, however, 
be explained by increased coverage of 
PMTCT and HIV treatment services in 
our target communities. It is possible 
that investment at our pilot sites may 
have resulted in both a greater supply 
of PMTCT services and an increase in 
demand. Indeed, we observed that the 
proportion of HIV-infected women who 
knew their HIV status during pregnancy 
increased between the two surveys, as 
did the proportion who reported HIV 
testing during their last pregnancy and 
the proportion that started any form of 
antiretroviral prophylaxis. It is certainly 
plausible that community outreach ef-
forts and additional human resources 
associated with the pilot programme 
benefited all HIV-infected pregnant 
women, whether or not they eventu-
ally started combination antiretroviral 
regimens. This broader influence of 
PMTCT services should be considered 
when national programmes seek to scale 
up the implementation of Option B or 
Option B+.31 Each step of the PMTCT 
cascade must be addressed at the health 
systems level if we are to maximize the 
effect of interventions implemented 
during pregnancy and breastfeeding.32
This study assessed the effective-
ness of the pilot PMTCT programme 
using community-based household 
surveys, which is one of five approaches 
endorsed by WHO.33 However, we 
encountered several unanticipated 
challenges. The proportion of eligible 
households that refused to participate 
in the first survey was much higher 
than in the second: 11.3% versus 1.6%, 
respectively (Fig. 1). The number of 
refusals declined at each of the four 
study sites; the greatest difference was 
noted in the Kafue Missions catch-
ment area, where the proportion 
decreased from 22.2% to 1.2%. There 
was anecdotal evidence that our first 
survey coincided with the circulation 
of negative rumours about clinical 
research, which may explain the high 
refusal rate. It is important, therefore, 
that extensive, sustained outreach work 
be carried out during study implemen-
tation. We failed to collect information 
about which mothers participated in 
both surveys. However, the overlap is 
likely to be low because the latest de-
mographic and health survey in Zambia 
indicated that only 15.2% of women 
with a recent pregnancy reported the 
delivery of another child within the 
previous 24 months.34 Moreover, since 
our surveys took place more than two 
years apart, no HIV-exposed child aged 
under 24 months could have been in-
cluded in both surveys. In addition, we 
acknowledge that our estimates of HIV-
free survival have not been validated 
against a gold standard metric, as could 
be achieved by longitudinal follow-up 
of HIV-exposed infants over time. Cur-
rently, this is being remedied in a study 
funded by the United States National 
Institutes of Health (clinicaltrials.gov 
ID: NCT01951794). While the precision 
of our estimates for HIV-free survival 
requires confirmation, we believe our 
comparisons are valid because we used 
the same methods in both surveys.
Table 3. Factors associated with HIV infection or death before 24 months in children 
born to HIV-infected mothers, Kafue district of Zambia, 2009–2011
Factor Hazard ratio for HIV infection or death (95% CI)a
Unadjusted Adjusted
Reported PMTCT therapy
Combination antiretroviral regimen 0.24 (0.11–0.52) 0.33 (0.15–0.73)
Other therapy 1.30 (0.85–2.00) 1.39 (0.87–2.23)
No antiretroviral prophylaxis 1.0 1.0
Maternal age at time of survey, 
years
15 to < 25 1.0 1.0
25 to < 35 1.52 (0.72–3.22) 1.67 (0.94–2.96)
≥ 35 0.53 (0.16–1.75) 1.10 (0.49–2.44)
Parity
0–1 1.0 1.0
2–3 1.08 (0.53–2.21) 0.62 (0.35–1.10)
≥ 4 0.38 (0.17–0.82) 0.54 (0.29–0.99)
Educational level
No schooling or primary 1.32 (0.72–2.39) 1.13 (0.74–1.73)
Secondary or higher 1.0 1.0
Marital status
Married or cohabitating 1.0 1.0
Single or widowed 0.79 (0.33–1.89) 1.07 (0.65–1.75)
One or more institutional 
antenatal care visits
Yes 1.0 1.0
No 0.14 (0.06–0.31) 0.59 (0.23–1.52)
Institutional delivery
Yes 1.0 1.0
No 1.65 (0.89–3.08) 1.28 (0.83–1.96)
Infant breastfed at birth
Yes 1.0 1.0
No 0.30 (0.12–0.76) 0.66 (0.24–1.76)
Survey
First (before PMTCT programme) 1.0 1.0
Second (after PMTCT programme) 0.38 (0.20–0.72) 0.52 (0.34–0.80)
CI: confidence interval; HIV: human immunodeficiency virus; PMTCT: prevention of mother-to-child 
transmission.
a  In the multivariate analysis, adjustment was made for the health-care facility in which the programme 
was implemented.
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ملخص
نظم العالج التوليفي الشامل بمضادات الفريوسات القهقرية لتوقي انتقال فريوس العوز املناعي البرشي من األم إىل 
الطفل يف املناطق الريفية يف زامبيا: دراسة متعددة القطاعات من جولتني
الغرض تقييم ما إذا كان الربنامج التجريبي لتوقي انتقال فريوس 
العوز املناعي البرشي من األم إىل الطفل مرتبطًا بالتغريات يف البقاء 
يف  السكان  صعيد  عىل  املبكرة  الطفولة  مرحلة  يف  احلياة  قيد  عىل 
املناطق الريفية يف زامبيا.
الفريوسات  بمضادات  التوليفي  العالج  نظم  تقديم  تم  الطريقة 
القهقرية إىل النساء احلوامل واملرضعات املصابات بعدوى فريوس 
العوز املناعي البرشي، بغض النظر عن حالتهن املناعية، يف أربعة 
شهرًا   24 سن  يف  األطفال  بقاء  حتديد  وتم  ريفية.  صحية  مرافق 
بني  البرشي  املناعي  العوز  بفريوس  اإلصابة  دون  احلياة  قيد  عىل 
العوز  فريوس  بعدوى  مصابات  ألمهات  ولدوا  الذين  األطفال 
إىل  األم  من  االنتقال  توقي  برنامج  تنفيذ  قبل  البرشي  املناعي 
الطفل وبعده باستخدام دراسات استقصائية جمتمعية. وتم اختيار 
األرس املعيشية عشوائيًا ومطالبة النساء الاليت ولدن خالل األربع 
والعرشين شهرًا السابقة باملشاركة. وتم اختبار األمهات للكشف 
األطفال  اختبار  وتم  البرشي،  املناعي  العوز  فريوس  أضداد  عن 
البرشي  املناعي  العوز  بفريوس  مصابات  ألمهات  ولدوا  الذين 
للكشف عن احلمض الريبي النووي منزوع األكسجني الفريويس. 
املرتبطة  العوامل  لتحديد  املتغريات  متعددة  نامذج  استخدام  وتم 
بإصابة الطفل بعدوى فريوس العوز املناعي البرشي أو وفاته.
سيدة   1778 إمجايل  من  سيدة   335 اختبار  نتيجة  كانت  النتائج 
)18.8 %( يف الدراسة االستقصائية األوىل )من 2008 إىل 2009( 
إجيابية لفريوس العوز املناعي البرشي. وكانت نتيجة اختبار 390 
سيدة من إمجايل 2386 سيدة )16.3 %( يف الدراسة االستقصائية 
الثانية )2011( إجيابية. وكان بقاء األطفال يف سن 24 شهرًا عىل 
قيد احلياة دون اإلصابة بفريوس العوز املناعي البرشي يف األطفال 
الثقة  )فاصل   0.66 البرشي  املناعي  العوز  لفريوس  املعرضني 
االستقصائية  الدراسة  يف   )0.76–  0.63 الثقة:  فاصل   ،% 95
األوىل و0.89 )فاصل الثقة: 95 %، فاصل الثقة: 0.83 –0.94( 
العالج  نظام  استخدام  وكان  الثانية.  االستقصائية  الدراسة  يف 
بانخفاض  مرتبطًا  القهقرية  الفريوسات  بمضادات  التوليفي 
خماطر اإلصابة بعدوى فريوس العوز املناعي البرشي أو الوفاة يف 
 ،% 95 الثقة:  فاصل   ،0.33 املصححة:  املخاطر  )نسبة  األطفال 
بحالة  األمهات  معرفة  وازدادت   .)0.73–  0.15 الثقة:  فاصل 
فريوس العوز املناعي البرشي واستخدام اختبارات فريوس العوز 
بني  احلمل  أثناء  التوليفي  العالج  نظم  واستخدام  البرشي  املناعي 
الدراسات االستقصائية.
االستنتاج ارتبط برنامج توقي االنتقال من األم إىل الطفل بازدياد 
بقاء األطفال الذين ولدوا ألمهات مصابات بعدوى فريوس العوز 
املناعي البرشي عىل قيد احلياة دون اإلصابة بفريوس العوز املناعي 
فريوس  الختبارات  األمهات  استخدام  كذلك  وازداد  البرشي. 
العوز املناعي البرشي وعالجه يف املجتمع املحيل.
In conclusion, this pilot PMTCT 
programme in rural Zambia was associ-
ated with an increase in the 24-month 
HIV-free survival in children born to 
HIV-infected mothers; however, we 
were unable to quantify the contribution 
of specific programme features to health 
outcomes. Increased investment at the 
pilot sites probably contributed to the 
observed improvements in health by in-
creasing both the supply of and demand 
for PMTCT services. Countries plan-
ning to incorporate WHO’s Option B 
or Option B+ strategy for PMTCT into 
their national PMTCT policies should 
bear in mind the importance of health 
systems capacity to support the effec-
tive incorporation of more efficacious 
regimens. ■
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Fig. 8. Proportiona of HIV-infected mothers who reported using a combination 
antiretroviral regimen during their last pregnancy, by health-care facility, before 
and after the pilot programme to prevent mother-to-child transmission (PMTCT) 
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PMTCT 计划实施之前和之后 HIV 感染母亲生育的孩
子中 24 月无 HIV 存活情况。随机选择家庭，并要求




结果 在第一次调查中（2008–2009 年），1778 名妇女
中有 335 名（18.8%）检测 HIV 阳性。在第二次调查中
（2011 年），2386 名中有 390（16.3%）名检测阳性。在




95% CI ：0.15–0.73）。在两次调查之间，母亲 HIV 知
识的状态、使用 HIV 检测和在怀孕期间使用联合治疗
方案的情况有所增强。
结论 PMTCT 计划与 HIV 感染母亲所生儿童更高的无
HIV 生存率有关。社区中母亲使用 HIV 检测和治疗也
有增加。
Résumé
Thérapies antirétrovirales combinées universelles pour prévenir la transmission mère-enfant du VIH en Zambie rurale: une 
étude transversale en deux tours
Objectif Évaluer si un programme pilote pour prévenir la transmission 
mère-enfant (PTME) du virus de l’immunodéficience humaine (VIH) est 
associé à des changements en matière de survie du jeune enfant au sein 
de la population dans les régions rurales de la Zambie.
Méthodes Des thérapies antirétrovirales combinées ont été 
proposées à des femmes infectées par le VIH, enceintes et allaitantes, 
indépendamment de leur statut immunologique, dans quatre centres de 
santé ruraux. La survie sans VIH à 24 mois chez les enfants nés de mères 
infectées par le VIH a été déterminée avant et après la mise en œuvre du 
programme PTME à l’aide d’enquêtes communautaires. Les ménages 
ont été choisis de manière aléatoire, et il a été demandé aux femmes 
qui avaient accouché au cours des 24 derniers mois, d’y participer. 
On a testé la présence d’anticorps anti-VIH chez les mères et d’acide 
désoxyribonucléique viral chez les enfants nés de mères infectées par le 
VIH. Des modèles à variables multiples ont été utilisés pour déterminer 
les facteurs associés à l’infection par le VIH ou au décès de l’enfant.
Résultats Dans la première étude (2008–2009), 335 femmes parmi 1778 
(18,8%) ont été testées positives à l’infection par le VIH. Dans la deuxième 
étude (2011), 390 femmes parmi 2386 (16,3%) ont été testées positives. 
La survie sans VIH à 24 mois chez les enfants exposés au VIH était de 0,66 
(intervalle de confiance de 95%, IC: 0,63–0,76) dans la première étude 
et de 0,89 (IC de 95%: 0,83–0,94) dans la seconde. La combinaison de la 
thérapie antirétrovirale était associée à un risque inférieur d’infection par 
le VIH ou de décès chez les enfants (rapport de risques ajusté: 0,33, IC de 
95%: 0,15–0,73). La connaissance du statut VIH des mères, l’utilisation 
des tests de dépistage du VIH et des traitements combinés pendant la 
grossesse ont augmenté entre les études.
Conclusion Le programme PTME était associé à une augmentation 
de la survie sans VIH chez les enfants nés de mères infectées par le VIH. 
L’utilisation par les mères du dépistage et du traitement contre le VIH a 
également augmenté au sein de la communauté.
Резюме
Схемы универсальной комбинированной антиретровирусной терапии для предотвращения передачи 
ВИЧ от матери к ребенку в сельских районах Замбии: двухэтапное поперечное исследование
Цель Определить, связана ли пилотная программа по 
предотвращению передачи от матери к ребенку (ППМР) вируса 
иммунодефицита человека (ВИЧ) с изменениями в уровне 
выживаемости в раннем детском возрасте в сельских районах 
Замбии.
Методы В четырех сельских медицинских учреждениях 
беременным и кормящим ВИЧ-инфицированным женщинам 
предлагалась комбинированная антиретровирусная терапия 
вне зависимости от их иммунологического статуса. До и 
после реализации программы ППМР на основе исследований 
общин были определены уровни 24-месячной выживаемости 
без ВИЧ среди детей, рожденных от ВИЧ-инфицированных 
матерей. Домохозяйства выбирались случайным образом, 
и женщинам, родившим в течение последних 24 месяцев, 
предлагалось принять участие в исследовании. Матери были 
протестированы на наличие антител к ВИЧ, а дети, рожденные от 
ВИЧ-инфицированных матерей, были проверены на наличие ДНК 
ВИЧ. Для определения факторов, связанных с инфицированием 
детей ВИЧ или смертью, использовались многопараметрические 
модели.
Результаты В первом исследовании (2008–2009 гг.) 335 из 
1778 женщин (18,8%) имели положительный результат на ВИЧ. 
Во втором исследовании (2011 г.) положительный результат 
показали 390 из 2386 (16,3%) обследованных женщин. Уровень 
24-месячной выживаемости без ВИЧ у детей, подверженных 
ВИЧ, составил 0,66 (95% доверительный интервал, ДИ: 0,63–0,76) 
в первом исследовании и 0,89 (95% ДИ: 0,83–0,94) – во втором. 
Применение комбинированной антиретровирусной терапии 
сопровождалось более низким риском инфицирования ВИЧ 
или смерти у детей (скорректированное отношение рисков: 0,33, 
95% ДИ: 0,15–0,73). Осведомленность матерей о ВИЧ-статусе, 
использование тестов на ВИЧ и применение комбинированной 
терапии во время беременности возросло в период между 
исследованиями.
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Вывод Программа ППМР сопровождалась увеличением 
выживаемости без ВИЧ у детей, рожденных от ВИЧ-
инфицированных матерей. Также увеличилось число матерей 
в сельских общинах, проходящих проверку и лечение ВИЧ-
инфекции.
Resumen
Tratamientos antirretrovirales de combinación universal para prevenir la transmisión maternoinfantil del VIH en las zonas 
rurales de Zambia: un estudio transversal de dos vueltas
Objetivo Evaluar si un programa piloto para prevenir la transmisión 
maternoinfantil (PTMI) del virus de la inmunodeficiencia humana (VIH) 
está asociado a cambios en la supervivencia en la primera infancia a 
nivel de población en las zonas rurales de Zambia.
Métodos Se ofreció una combinación de tratamientos antirretrovirales 
a mujeres embarazadas y lactantes infectadas por el VIH, 
independientemente de su estado inmunológico, en cuatro centros 
de salud rurales. Mediante encuestas en la comunidad se determinó 
una supervivencia sin VIH de veinticuatro meses entre los niños 
nacidos de madres infectadas por el VIH antes y después de la 
implementación del programa PTMI. Los hogares se seleccionaron al 
azar y se pidió que participaran las mujeres que habían dado a luz en 
los 24 meses anteriores. Las madres se sometieron a una prueba para 
detectar los anticuerpos contra el VIH y se realizó una prueba del ácido 
desoxirribonucleico viral a los niños nacidos de madres infectadas con 
VIH. Se utilizaron modelos multivariables para determinar los factores 
asociados con la infección o muerte por VIH del niño.
Resultados En la primera encuesta (2008–2009), 335 de 1778 mujeres 
(18,8 %) dieron positivo en el VIH. En la segunda (2011), dieron positivo 
390 de 2386 (16,3 %). La supervivencia sin VIH de 24 meses en los 
niños expuestos al VIH fue del 0,66 (intervalo de confianza del 95 %, IC: 
0,63–0,76) en la primera encuesta y del 0,89 (IC del 95 %: 0,83–0,94) 
en la segunda. La combinación de un tratamiento antirretroviral se 
asoció con un menor riesgo de infección por VIH o muerte en los niños 
(razón de riesgo ajustada: 0,33, IC del 95 %: 0,15–0,73). El conocimiento 
de las madres de su estado serológico, el uso de pruebas para el VIH y 
los tratamientos combinados durante el embarazo aumentaron en el 
tiempo transcurrido entre las encuestas.
Conclusión El programa PTMI estuvo asociado a un aumento de la 
supervivencia sin VIH en los niños nacidos de madres infectadas por el 
VIH. La utilización materna de la prueba y el tratamiento del VIH en la 
comunidad también aumentó.
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Fig. 5. Proportiona of HIV-infected mothers who knew their HIV status, by health-
care facility, before and after the pilot programme to prevent mother-to-child 
transmission (PMTCT) of the human immunodeficiency virus (HIV) in the Kafue 
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Fig. 6. Proportiona of HIV-infected mothers tested for HIV during their last pregnancy, 
by health-care facility, before and after the pilot programme to prevent mother-
to-child transmission (PMTCT) of the human immunodeficiency virus (HIV) in the 
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Fig. 7. Proportiona of HIV-infected mothers who reported using any antiretroviral 
prophylaxis during their last pregnancy, by health-care facility, before and after 
the pilot programme to prevent mother-to-child transmission (PMTCT) of the 
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